%PDF-1.4
%
64 0 obj
<>
endobj
61 0 obj
<>
endobj
129 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-03-02T11:03:53Z
2024-03-28T05:14:28-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T05:14:28-07:00
application/pdf
Heather
2003-103.april
uuid:05cda984-1dd2-11b2-0a00-8e0827bd3700
uuid:05cda987-1dd2-11b2-0a00-5b0000000000
endstream
endobj
50 0 obj
<>
endobj
51 0 obj
<>
endobj
65 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 34 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 36 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 38 0 R/Type/Page>>
endobj
17 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 40 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
23 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
151 0 obj
[155 0 R]
endobj
152 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(2.)-875.1 (W)79.9 (ebb )54.8 (AC, Collins KL, )54.8 (Auron PE, et al. Intereukin-1 gene \(IL1\))]TJ
1.675 -1.25 Td
[(assigned to long arm of human chromosome 2. L)54.8 (ymphokine Res)]TJ
0 Tc 0 Tw 0 -1.25 TD
(1986;5:77-85.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(3.)-875.1 (Bidwell JL. Cytokine gene polymorphisms in human disease: on-)]TJ
1.675 -1.25 Td
[(line database [Internet]. )54.8 (A)73.9 (vailable from http://bris.ac.uk/pathand-)]TJ
0 Tw T*
(micro/services/GAI/polymorphisms.html)Tj
0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Di Giovine FS, )17.7 (T)69.9 (akhsh E, Blakemore )54.8 (AIF)79.7 (, Duf)17.7 (f GW)91.7 (. Single base)]TJ
1.675 -1.25 Td
[(polymorphism at \32051)36.8 (1 in the human interleukin-1\247 \(IL1\247\) gene.)]TJ
T*
(Hum Mol Genet 1992;1:450.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Guasch JF)79.7 (, Bertina RM, Reitsma PH. Five novel intragenic)]TJ
1.675 -1.25 Td
(dimorphisms in the human interleukin-1 genes combine to high)Tj
0 Tc T*
[(informativity)64.9 (. Cytokine 1996;8:598-602.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875.1 (Langdahl BL, L\277kke E, Carstens M, Stenkj\276r LL, Eriksen EF)79.7 (.)]TJ
1.675 -1.25 Td
(Osteoporotic fractures are associated with an 86-base pair repeat)Tj
T*
(polymorphism in the interleukin-1-receptor antagonist gene but not)Tj
T*
(with polymorphisms in the interleukin-1\247 gene. J Bone Miner Res)Tj
0 Tc 0 Tw T*
(2000;15:402-14.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875.1 (Pociot F)79.7 (,)-0.1 ( M\277lvig J, )17.7 (W)79.9 (ogensen L, )17.7 (W)79.9 (orsaae H, Nerup J. )54.8 (A)-202.3 (T)69.9 (aq I)]TJ
1.675 -1.25 Td
(polymorphism in the human interleukin-1\247 gene correlates with )Tj
T*
(IL-1\247 \(IL1\247\) secretion in vitro. Eur J Clin Invest 1992;22:396-4\
02.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA)-220.2 (allele2)]TJ
1.675 -1.25 Td
(\(IL1RN*2\) is associated with enhanced IL-1\247 production in vitro.)Tj
T*
(Scand J Immunol 1998;47:195-8.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (EI-Omar EM, Carrington M, Chow )17.7 (WH, et al. Interleukin-1 poly-)]TJ
1.675 -1.25 Td
[(morphisms associated with increased risk of gastric cancer)54.8 (. Nature)]TJ
0 Tc 0 Tw T*
(2000;404:398-402.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Cvetkovic JT)73.9 (, )17.7 (W\214llber)17.7 (g-Jonsson S, Stegmayr B, Rantap\212\212-)]TJ
2.175 -1.25 Td
[(Dahlqvists, Levert )54.8 (AK. Susceptibility for and clinical)]TJ
T*
(manifestations of rheumatoid arthritis are associated with)Tj
T*
[(polymorphisms of the )17.7 (TNF-a, IL-1\247, and IL-1Ra genes. )]TJ
T*
(J Rheumatol 2002; 29: 212-9.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Buchs N, Di Giovine FS, Silvestri )17.7 (T)74 (,)-0.1 ( )17.7 (V)110.8 (annier E, Duf)17.7 (f GW)91.7 (, Miossec)]TJ
2.1381 -1.25 Td
[(P)110.8 (. IL-1\247 and IL-1Ra gene polymorphisms and disease severity in)]TJ
T*
(rheumatoid arthritis: interaction with their plasma levels. Genes)Tj
T*
(Immun 2001;2:222-8.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Huang CM, )17.7 (T)69.9 (sai FJ, )17.7 (W)39.8 (u JY)128.8 (, )17.7 (W)39.8 (u MC. Interleukin-1\247 and)]TJ
2.175 -1.25 Td
(interleukin-1 receptor antagonist gene polymorphisms in)Tj
T*
(rheumatoid arthritis. Scand J Rheumatol 2001;30:225-8.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Cantagrel )54.8 (A, Navaux F)79.7 (, Loubet-Lescouli\216 P)110.7 (, et al. Interleukin-1\247,)]TJ
2.175 -1.25 Td
(interleukin-1 receptor antagonist, interleukin-4, and interleukin-10)Tj
T*
[(gene polymorphisms. )54.8 (Arthritis Rheum 1999;42:1093-100.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (Moos )17.7 (V)128.9 (, Rudwaleit M, Herzog )17.7 (V)128.9 (, H\232ling K, Sieper J, M\237ller B.)]TJ
2.175 -1.25 Td
[(Association of genotypes af)17.7 (fecting the expression of interleukin-1\247)]TJ
T*
[(or interleukin-1 receptor antagonist with osteoarthritis. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2000;43:2417-22.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875.1 (Mwantembe O, Gaillard MC, Barkhuizen M, et al. Ethnic)]TJ
2.175 -1.25 Td
[(dif)17.7 (ferences in allelic associations of the interleukin-1 gene cluster)]TJ
T*
[(in South )54.8 (Africa patients with inflammatory bowel disease \(IBD\))]TJ
T*
(and in control individuals. Immunogenetics 2001;52:249-54.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Hamajima N, Matsuo K, Saito )17.7 (T)74 (, et al. Interleukin-1)]TJ
2.175 -1.25 Td
(polymorphisms, lifestyle factors, and Helicobacter pylori infection.)Tj
T*
(Jpn J Cancer Res 2001; 92:383-9.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Niino M, Kikuchi S, Fukazawa )17.7 (T)74 (,)-0.1 ( )36.8 (Y)99.8 (abe I, Sasaki H, )17.7 (T)69.9 (ashiro K.)]TJ
2.175 -1.25 Td
(Genetic polymorphisms of IL-1 beta and IL-1 receptor antagonist)Tj
T*
(in association with multiple sclerosis in Japanese patients. )Tj
T*
[(J Neuroimmunol 2001;1)36.8 (18:295-9.)]TJ
30.825 68.75 Td
[(18.)-875.1 (T)69.9 (akamatsu M, )36.8 (Y)99.8 (amauchi M, Maezawa )36.8 (Y)128.9 (, Saito S, Maeyama S,)]TJ
2.175 -1.25 Td
[(Uchikoshi )17.7 (T)74 (. Genetic polymorphisms of interleukin-1\247 in)]TJ
T*
(association with the development of alcoholic liver disease in)Tj
T*
[(Japanese patients. )54.8 (Am J Gastroenterol 2000;95:1305-1)36.8 (1.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (Huang CM, )17.7 (W)39.9 (u)-0.1 ( MC, )17.7 (W)39.9 (u JY)128.8 (, )17.7 (T)69.9 (sai FJ. Lack of association of)]TJ
2.175 -1.25 Td
(interleukin-1\247 gene polymorphisms in Chinese patients with)Tj
T*
(systemic lupus erythematosus. Reumatol Int 2002;21:173-5.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Jonsson R, Haga HJ, Gordon )17.7 (TP)110.8 (. Current concepts on diagnosis,)]TJ
2.175 -1.25 Td
[(autoantibodies and therapy in Sj\232gren\325)54.8 (s syndrome. Scand J)]TJ
T*
(Rheumatol 2000;29:341-8.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (Azuma M, Motegi K, )54.8 (Aota K, Hayashi )36.8 (Y)128.9 (, Sato M. Role of)]TJ
2.175 -1.25 Td
[(cytokines in the destruction of acinar structure in Sj\232gren\325)54.8 (s)]TJ
T*
(syndrome salivary glands. Lab Invest 1997;77:269-80. )Tj
-2.175 -1.25 Td
[(22.)-875.1 (Fox RI, Kang HI, )54.8 (Ando D, )54.8 (Abrams J, Pisa E. Cytokine mRNA)]TJ
2.175 -1.25 Td
[(expression in salivary gland biopsies of Sj\232gren\325)54.8 (s syndrome. )]TJ
T*
(J Immunol 1994;152:5532-9.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (Solomon )54.8 (A, Dursun D, Liu Z, Xie )36.8 (Y)128.9 (, Macri )54.8 (A, Pflugfelder SC. Pro-)]TJ
2.175 -1.25 Td
(and anti-inflammatory forms of interleukin-1 in the tear fluid and)Tj
T*
[(conjunctiva of patients with dry-eye disease. Invest Ophthalmol )17.7 (V)59.8 (i)0.1 (s)]TJ
T*
(Sci 2001;42:2283-92.)Tj
-2.175 -1.25 Td
[(24.)-875.1 (Magusson )17.7 (V)128.9 (,)-0.1 ( Nakken B, Bolstad )54.8 (AI, )54.8 (Alarc\227n-Riquelme ME.)]TJ
2.175 -1.25 Td
(Cytokine polymorphisms in systemic lupus erythematosus and)Tj
T*
[(Sj\232gren\325)54.8 (s syndrome. Scand J Immunol 2001;54:55-61.)]TJ
-2.175 -1.25 Td
[(25.)-875.1 (Fujibayashi )17.7 (T)74 (, Sugai S, Miyasaka N, )17.7 (T)69.9 (ojo )17.7 (T)74 (, Miyawaki S, Ichikawa)]TJ
2.175 -1.25 Td
[(Y)128.9 (,)-0.1 ( )17.7 (T)35 (ubota K. Revised Japanese criteria for Sj\232gren\325)54.8 (s syndrome.)]TJ
T*
[(Autoimmune Disease Research Committee )54.8 (Annual report of)]TJ
T*
[(Ministry of the Health and )17.7 (W)79.9 (elfare. )17.7 (T)69.9 (okyo: Ministry of the Health)]TJ
0.00729 Tw T*
[(and W)79.9 (elfare; )-17.7 (1999:135-8.)]TJ
0.02499 Tw -2.175 -1.25 Td
[(26.)-875.1 (Hochber)17.7 (g MC. Updating the )54.8 (American College of Rheumatology)]TJ
2.175 -1.25 Td
(revised criteria for the classification of systemic lupus)Tj
T*
[(erythematosus. )54.8 (Arthritis Rheum 1997;40:1725.)]TJ
-2.175 -1.25 Td
[(27.)-875.1 (Abecasis GR, Cookson )17.7 (WOC. GOLD. Graphical overview of)]TJ
2.175 -1.25 Td
(linkage disequilibrium. Bioinformatics 2000;16:182-3.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (Le Loet X. Evaluation of the clinical activity of systemic lupus)]TJ
2.175 -1.25 Td
[(erythematosus. )54.8 (Ann Med Interne Paris 1990;141:261-4.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (Ohyama )36.8 (Y)128.9 (, Nakamura S, Matsuzaki G, et al. Cytokine messenger)]TJ
2.175 -1.25 Td
[(RNA)-220.2 (expression in labial salivary glands of patients with Sj\232gren\325)54.8 (s)]TJ
T*
[(syndrome. )54.8 (Arthritis Rheum 1996;39:1376-84)]TJ
-2.175 -1.25 Td
[(30.)-875.1 (Matsumoto I, Okada S, Kuroda K, et al. Single cell analysis of )17.7 (T)]TJ
2.175 -1.25 Td
[(cells infiltrating labial salivary glands from patients with Sj\232gren\325\
)54.8 (s)]TJ
T*
(syndrome. Int J Mol Med 1999;4:519-27.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (Chrousos GP)110.8 (. )17.7 (The hypothalamic-pituitary-adrenal axis and immune-)]TJ
2.175 -1.25 Td
(mediated inflammation. N Engl J Med 1995;332:1351-62.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Fibbe )17.7 (WE, Daha MR, Hiemstra PS, et al. Interleukin 1 and poly\(rI\))]TJ
2.175 -1.25 Td
[(poly\(rC\) induced production of granulocyte CSF)79.7 (, macrophage CSF)79.7 (,)]TJ
T*
(and granulocyte-macrophage CSF by human endothelial cells. Exp)Tj
T*
(Hematol 1989;17:229-34.)Tj
-2.175 -1.25 Td
[(33.)-875.1 (Hulkkonen J, Laippala P)110.7 (, Hurme M. )54.8 (A)-220.1 (rare allele combination of)]TJ
2.175 -1.25 Td
(the interleukin-1 gene complex is associated with high interleukin-)Tj
T*
(1\247 plasma levels in healthy individuals. Eur Cytokine Netw)Tj
0 Tc T*
[(2000;1)36.9 (1: 251-5.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
-0.00011 Tc 8 0 0 8 54.5 35.9844 Tm
(Muraki, et al: IL-1\247 gene polymorphisms in SS and SLE)Tj
0 Tc 0 Tw 61.4375 -0.0313 Td
(725)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
44 0 obj
<>stream
8;Z\6$Wc:A%+P5/W9`fuH9QANOCf0_j)"o5W"jYA)NC3]`"Tm9,5A9IJ%o<>][ktY
I(f,t`B3nl=mYn.)=->9YZ75J:60:fB#Se@5Mu?+O,:IPJ9gQbiFV&jl2MgE3^F7c
^b*]NLZYC1MLoXLb)pZ.piP!$5f'&9PQgmKsad-m,WQob+cJ7Xr;`6e$:%%Ki97
l]Tm7Hr+#;66%#^Ku^"mZm-D3@AloL6n)T3LC:\-ibn=@-ORYh0@4Rhc"9ukhhF9n
#UiU*ChBh<*QedRXm0@%N)g$WKjE0Gm:*9'p.cl)U99cKm"t`gW>d:#4OQW`7dWm=
"\psme&WMUGt0neCoHb@im*YW7>bVM]&:Xe[$0t4AkL\)YiZZ&l,$bLGGSu,g`&"m
1SpOd&Y!JsY)\4JMa7H!FDC]qN\[YSQ^?J2m"6'B>h0KN!uY#N"h*-"^n/-=lt.=a
[[i0Dr35aiK"p1l8d01CSm2XF52hj!;ns(BDc*3o?&B`4P@cVgqj@tZ-Cn>7AaP@O
6b4E-=:J(VX1]n9gEie'BhS)BQ6W8MT^sDDY%*Am&mJojmY.X0g=HNW!XCLr!(e[+
I&hVIZ4@5eY[R$\2T/W<+@FA%hWq:#sJeJP/f)ca@In(l^^<\>tt+3I.2CK/>KQ&Yj`p
%encX@:)UY4'@^!&[Dq-B]iaa9<]\^h$D(OWb4\@Km6ZkIM<2(nKJ
#Z5[`jZRHc*Icuq_L06!i+0f8+CPG:eBdLErK4!:Wnqb'aqIQ5nK1/H*g^^6c&Pl]
:*2q"nc&$'O)pnN56CoY#Y&&~>
endstream
endobj
48 0 obj
[/Indexed/DeviceRGB 255 47 0 R]
endobj
47 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
103 0 obj
<>
endobj
72 0 obj
<>
endobj
67 0 obj
<>
endobj
116 0 obj
<>
endobj
134 0 obj
<>
endobj
68 0 obj
<>
endobj
95 0 obj
<>stream
H{PSWro./QZnUDK֢⫀<K)H ! Hx<QZ_X-sպjvNxٍ3;sf~s
-[?]aAD*V,ڬ~}`,mú[\\4זrj$}C4/*z
C
teSK7wwu\;ђ.|O"(YXCP
2yLGD^qq\H.VI bD!)Qbi|HG#) bFQD|b\$)T
I$B.+FcuaSl0{)[akig*VakaFb1?,U8kʦLxmxK/yz:rZh:>`Ƿ$IՓ&'?nr_LO3/jj_]qpH/-GFs|I38wٹ]ij.5#n!w+-g{
1ũZuFvYӮP$KSiytn.() k@ϠD_HxQ(q#3Z[VY&Sd.fft.2 [9&"Wj֤.7]: l9)Hw%3W2G4߂CsT9 +`X4hqK; LbF׀4NI]sY@]^ܾL]sB?ZȰ}iuiWt= h(?NRvSs[ 7? $R*ݎl5%y֚n_4m?)P
QXO7Cq?44o:kX$ie*rSu@d|\Iv$dŨ%fhI*-<m({HCQo#:[xǮ91}k҈ÕaufƅI:W, ghy:0HQ@>$
aWpN7UP4p 5 -tn۸.=!/^aHJԊԞ